Get the Stockscreener App
44.97
1.96%
-0.90
Merus N V Stock (MRUS) Latest News
Merus (NASDAQ:MRUS) Shares Sold by Great Point Partners LLC - MarketBeat
Westfield Capital Management Co. LP Invests $30.40 Million in Merus (NASDAQ:MRUS) - MarketBeat
The Goldman Sachs Group Begins Coverage on Merus (NASDAQ:MRUS) - Defense World
When (MRUS) Moves Investors should Listen - Stock Traders Daily
Algert Global LLC Has $7.68 Million Stake in Merus (NASDAQ:MRUS) - MarketBeat
Merus (NASDAQ:MRUS) Earns “Buy” Rating from Needham & Company LLC - Defense World
Merus NV (MRUS): Among the Most Promising Cancer Stocks According to Hedge Funds - Insider Monkey
10 Most Promising Cancer Stocks According to Hedge Funds - Insider Monkey
Goldman Sachs Initiates Coverage of Merus N.V. (MRUS) with Buy Recommendation - MSN
Biotech Stock Boosted on Brand-New 'Buy' Rating - Schaeffers Research
Merus stock a 'buy' for Goldman, driven by peto's market potential in HNSCC - Investing.com
Merus initiated with a Buy at Goldman Sachs - TipRanks
Merus (NASDAQ:MRUS) Earns "Buy" Rating from Needham & Company LLC - MarketBeat
First Turn Management LLC Sells 13,892 Shares of Merus (NASDAQ:MRUS) - MarketBeat
37,426 Shares in Merus (NASDAQ:MRUS) Acquired by State of New Jersey Common Pension Fund D - Defense World
State of New Jersey Common Pension Fund D Makes New Investment in Merus (NASDAQ:MRUS) - MarketBeat
Merus is Now Oversold (MRUS) - Nasdaq
Merus management to meet with Truist - TipRanks
GSA Capital Partners LLP Takes $675,000 Position in Merus (NASDAQ:MRUS) - MarketBeat
2,054 Shares in Merus (NASDAQ:MRUS) Purchased by US Bancorp DE - Defense World
Commodore Capital LP Bolsters Stake in Merus NV - GuruFocus.com
SAMLYN CAPITAL, LLC Bolsters Stake in Merus NV - GuruFocus.com
(MRUS) Trading Report - Stock Traders Daily
Is Merus N.V. (MRUS) Top Performing European Stock Heading into 2025? - MSN
FMR LLC Bolsters Stake in Merus NV - GuruFocus.com
10 Top Performing European Stocks Heading into 2025 - Insider Monkey
Merus (NASDAQ:MRUS) Shares Bought by TimesSquare Capital Management LLC - MarketBeat
US FDA extends review of Merus' gene-targeting cancer therapy - MSN
Merus (NASDAQ:MRUS) Given Consensus Recommendation of “Buy” by Brokerages - Defense World
Merus (NASDAQ:MRUS) Receives $86.70 Consensus Price Target from Brokerages - MarketBeat
MRUSMerus N.V. Common Shares Latest Stock News & Market Updates - StockTitan
Merus to Present at Upcoming Investor Conferences - The Manila Times
Merus Receives FDA extension of PDUFA for zenocutuzumab - GlobeNewswire
FDA extends review date for Merus' cancer drug Zeno By Investing.com - Investing.com Canada
FDA extends review date for Merus' cancer drug Zeno - Investing.com India
Merus (NASDAQ:MRUS) Shares Gap DownHere's Why - MarketBeat
Merus: Petosemtamab Set Up For December 2024 Data Presentation (NASDAQ:MRUS) - Seeking Alpha
FDA extends review period for Merus's cancer drug Zeno - Investing.com India
Merus : FDA Extends Review of Cancer Drug Zenocutuzumab to February - Marketscreener.com
US FDA extends review of Merus’ gene-targeting cancer therapy - PharmaLive
Merus says FDA extended review period for cancer drug - MSN
Merus stock slips as FDA delays drug review (MRUS:NASDAQ) - Seeking Alpha
FDA extends review period for Merus's cancer drug Zeno By Investing.com - Investing.com Canada
Harbor Capital Advisors Inc. Buys New Holdings in Merus (NASDAQ:MRUS) - MarketBeat
abrdn plc Invests $4.36 Million in Merus (NASDAQ:MRUS) - MarketBeat
Merus N.V. (MRUS) Reports Q3 Loss, Tops Revenue Estimates - MSN
Merus sees cash runway into 2028 - MSN
Merus reports Q3 EPS ($1.46), consensus (88c) - MSN
Merus annonce ses résultats financiers pour le troisième trimestre 2024 et fait le point sur ses activités - GlobeNewswire Inc.
Merus Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance
1.35%
0.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):